JPMorgan Chase & Co. started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note released on Monday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $34.00 price objective on the stock.
Separately, Cowen restated a buy rating on shares of Avrobio in a research note on Monday.
Shares of NASDAQ:STOK opened at $23.89 on Monday. Stoke Therapeutics has a 12-month low of $22.84 and a 12-month high of $31.76.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Recommended Story: Hedge Funds Explained
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.